

Notice of References Cited	Application/Control No. 10/816,276		Applicant(s)/Patent Under Reexamination BETTER ET AL.	
	Examiner Maher M. Haddad		Art Unit 1644	Page 1 of 1

U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
*	A	US-2003/0203447	10-2003	Horwitz, Arnold H.	435/69.1
	B	US-			
	C	US-			
	D	US-			
	E	US-			
	F	US-			
	G	US-			
	H	US-			
	I	US-			
	J	US-			
	K	US-			
	L	US-			
	M	US-			

FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N	WO 01/07082	02-2001	PCT	KNICK et al	-----
	O					
	P					
	Q					
	R					
	S					
	T					

NON-PATENT DOCUMENTS

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	XOMA Aleader in Therapeutic Antibodies, XOMA's Human Engineered™ ING-1 Cancer Antibody Shows Encouraging clinical Safety Profile and Low Immunogenicity in Patients. pages 1-2, May 20, 2002.
	V	Better et al. Recombinant human engineered ING-1 monoclonal antibody, ING-1 (heMAb), exhibits minimal immunogenicity in patients with advanced adenocarcinomas. Proc Am Soc Clin Oncol 21: May 2002 (abstr 75)
	W	Ammons et al. ING-1(heMAb), a Human Engineered Antibody to Ep-CAM Kills Tumor Cells in Vitro and in Vivo.Proc Am Soc Clin Oncol 20: 2001 (abstr 1099).
	X	

*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.